or Try an Advanced Search...

    Technical Analysis for FLGT - Fulgent Genetics, Inc.

    Grade Last Price % Change Price Change
    F 17.28 1.65% 0.28
    FLGT closed up 1.65 percent on Wednesday, November 20, 2024, on 1.35 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical FLGT trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Low Weakness 1.65%
    Outside Day Range Expansion 1.65%
    Wide Bands Range Expansion 1.65%
    Oversold Stochastic Weakness 1.65%
    New 52 Week Closing Low Bearish 3.41%
    NR7 Range Contraction 3.41%
    Older End-of-Day Signals for FLGT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above Previous Day's High about 21 hours ago
    Up 3% about 21 hours ago
    Up 2% about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    FLGT Chart by TradingView
    Basic chart:

    Profile

    Fulgent Genetics, Inc. Description

    Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Medicine Biotechnology Cancer Genetics Cardiovascular Disease Medical Genetics Neurological Disorders Medical Test Vascular Disease Molecular Diagnostics Algorithms Applied Genetics Urological Disorders Genetic Testing Qiagen

    Is FLGT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now
    Nov 11 Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
    Nov 10 Companies Like Fulgent Genetics (NASDAQ:FLGT) Are In A Position To Invest In Growth
    Nov 10 Fulgent Genetics Third Quarter 2024 Earnings: EPS Misses Expectations
    Nov 9 Fulgent Genetics Reports Strong Q3 2024 Results
    Nov 9 Fulgent Genetics Inc (FLGT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Decline
    Nov 8 Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
    Nov 8 Fulgent Genetics Non-GAAP EPS of $0.31 beats by $0.46, revenue of $71.74M in-line
    Nov 8 Fulgent Genetics Non-GAAP EPS of $0.31 beats by $0.46, revenue of $71.7M in-line
    Nov 8 Fulgent Reports Third Quarter 2024 Financial Results
    See more FLGT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 30.68
    52 Week Low 16.56
    Average Volume 184,797
    200-Day Moving Average 21.65
    50-Day Moving Average 20.41
    20-Day Moving Average 19.66
    10-Day Moving Average 18.52
    Average True Range 0.96
    RSI (14) 34.21
    ADX 35.41
    +DI 12.28
    -DI 33.97
    Chandelier Exit (Long, 3 ATRs) 20.00
    Chandelier Exit (Short, 3 ATRs) 19.43
    Upper Bollinger Bands 23.25
    Lower Bollinger Band 16.08
    Percent B (%b) 0.17
    BandWidth 36.46
    MACD Line -0.92
    MACD Signal Line -0.54
    MACD Histogram -0.3835
    Fundamentals Value
    Market Cap 512.06 Million
    Num Shares 29.6 Million
    EPS -2.10
    Price-to-Earnings (P/E) Ratio -8.23
    Price-to-Sales 2.68
    Price-to-Book 0.60
    PEG Ratio 1.32
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.36
    Resistance 3 (R3) 18.32 17.93 18.18
    Resistance 2 (R2) 17.93 17.65 17.95 18.12
    Resistance 1 (R1) 17.60 17.48 17.77 17.64 18.06
    Pivot Point 17.21 17.21 17.29 17.23 17.21
    Support 1 (S1) 16.88 16.93 17.05 16.92 16.50
    Support 2 (S2) 16.49 16.76 16.51 16.44
    Support 3 (S3) 16.16 16.49 16.38
    Support 4 (S4) 16.20